<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539613</url>
  </required_header>
  <id_info>
    <org_study_id>COH in ICSI</org_study_id>
    <nct_id>NCT04539613</nct_id>
  </id_info>
  <brief_title>Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH &amp; HMG Versus Rec-F.S.H Alone in ICSI Cycle</brief_title>
  <official_title>Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH &amp; HMG Versus Rec-F.S.H Alone in ICSI Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alaa Fouli Gaber Ebrahim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      despite the large number of papers published on COH protocols comparing the efficiency of&#xD;
      different exogenous gonadotropins, no confirmed protocol exists, and it is not quite clear&#xD;
      which is superior to the others.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      , the objective of the current study was to compare the efficacy of 2 different ovarian&#xD;
      stimulation protocols, comprising hpFSH, HMG versus R-FSH on oocyte and embryo quality and&#xD;
      IVF treatment outcome in patients undergoing IVF or intracytoplasmic sperm injection&#xD;
      (ICSI)(4).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fertility outcomes (pregnancy rate, abortion and live birth rate) in IVF patients.</measure>
    <time_frame>5months</time_frame>
    <description>(pregnancy rate, abortion and live birth rate) in IVF patients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Stimulation in ICSI</condition>
  <arm_group>
    <arm_group_label>group1</arm_group_label>
    <description>Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group2</arm_group_label>
    <description>Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPFSH &amp; HMG</intervention_name>
    <description>. Various gonadotropin preparations</description>
    <arm_group_label>group1</arm_group_label>
    <other_name>rec-F.S.H</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normal ovulatory function and normal semen analysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1-Aged 20-35 yr, male factor, 2-Tubal or unexplained infertility, 3-regular&#xD;
             menstruation cycle between 21 and 35 days, 4-Normal function of uterus according to&#xD;
             hysterosalpingography, hysteroscopy or transvaginal ultrasonography, 5-Normal ovaries&#xD;
             according to transvaginal ultrasonography during past 6 months prior to study and&#xD;
             compatible with normal adnexa and 6-Normal ovarian anatomy, and serum FSH level less&#xD;
             than 8 IU/l All women showed no recognizable endometriosis according to symptoms and&#xD;
             clinical examination in transvaginal ultrasonography or diagnostic laparoscopy.&#xD;
             7-7-All women have a history of unexplained infertility 8-Normal ovulatory function&#xD;
             and normal semen analysis according to the World Health Organization criteria .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other ovulation disorders such as hypo and hypergonadotropic,&#xD;
             hypogonadism, hyperprolactinemia.&#xD;
&#xD;
             2-Thyroid disorders. 3-Ovarian or adrenal neoplasms. 4-Cushing syndrome. 5-previous&#xD;
             history of systemic diseases such as endocrine and metabolic disorders.&#xD;
&#xD;
             6- Previous history of inappropriate ovarian response to stimulation with&#xD;
             gonadotropins (poor responders).&#xD;
&#xD;
             7-Prior history of more than 3 unsucce&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Amna Abdel sabour</last_name>
    <phone>01092405752</phone>
    <email>mannoon1991@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>kareem shaheen</last_name>
    <phone>01003957442</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>El neel</name>
      <address>
        <city>Minya</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kareem shaheen</last_name>
      <phone>+201003957442</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Kamel RM. The onset of human parturition. Arch Gynecol Obstet. 2010 Jun;281(6):975-82. doi: 10.1007/s00404-010-1365-9. Epub 2010 Feb 3. Review.</citation>
    <PMID>20127346</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Alaa Fouli Gaber Ebrahim</investigator_full_name>
    <investigator_title>Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH &amp; HMG Versus Rec-F.S.H Alone in ICSI Cycle</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

